Mersana Therapeutics, Inc.
MRSN
$0.3869
-$0.0131-3.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 52.89% | 63.65% | -78.48% | 18.50% | -27.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.89% | 63.65% | -78.48% | 18.50% | -27.14% |
| Cost of Revenue | 3.68% | -51.51% | -64.78% | -60.47% | -52.97% |
| Gross Profit | 45.11% | 90.34% | 60.98% | 76.08% | 65.20% |
| SG&A Expenses | -12.31% | -23.50% | -42.25% | -36.93% | -31.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.44% | -43.20% | -58.68% | -53.90% | -47.73% |
| Operating Income | 29.23% | 66.22% | 54.95% | 63.67% | 54.33% |
| Income Before Tax | 27.77% | 73.39% | 55.31% | 65.63% | 56.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.77% | 72.39% | 55.31% | 65.63% | 56.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.77% | 72.39% | 55.31% | 65.63% | 56.50% |
| EBIT | 29.23% | 66.22% | 54.95% | 63.67% | 54.33% |
| EBITDA | 29.64% | 66.95% | 55.41% | 64.20% | 55.03% |
| EPS Basic | 29.44% | 72.89% | 57.81% | 69.56% | 63.57% |
| Normalized Basic EPS | 27.66% | 67.47% | 57.80% | 69.56% | 64.50% |
| EPS Diluted | 29.44% | 72.89% | 57.81% | 69.37% | 63.57% |
| Normalized Diluted EPS | 27.66% | 67.47% | 57.80% | 69.56% | 64.50% |
| Average Basic Shares Outstanding | 2.44% | 1.83% | 5.91% | 12.94% | 19.40% |
| Average Diluted Shares Outstanding | 2.44% | 1.83% | 5.91% | 12.94% | 19.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |